Form 8-K - Current report:
SEC Accession No. 0001193125-24-262543
Filing Date
2024-11-20
Accepted
2024-11-20 16:15:29
Documents
18
Period of Report
2024-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d815860d8k.htm   iXBRL 8-K 40748
2 EX-4.1 d815860dex41.htm EX-4.1 70249
3 EX-10.1 d815860dex101.htm EX-10.1 231730
4 EX-10.2 d815860dex102.htm EX-10.2 101035
5 EX-99.1 d815860dex991.htm EX-99.1 9772
9 GRAPHIC g815860g1120100400745.jpg GRAPHIC 5380
  Complete submission text file 0001193125-24-262543.txt   699674

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20241119.xsd EX-101.SCH 2860
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20241119_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20241119_pre.xml EX-101.PRE 11268
20 EXTRACTED XBRL INSTANCE DOCUMENT d815860d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241480586
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)